Category Archives: Psoriasis

Li Xitian has developed thick, crusty patches of skin over his head, shoulders and back

FOR almost 40 years Li Xitian has suffered from an incurable skin condition that makes his skin as rough as tree bark.

Li, 58, is believed to be suffering from an extreme case of psoriasis a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

AsiaWire

AsiaWire

His crusty, bark-like skin has spread from his head to his back and down his legs.

His body now cracks as the thick, rough skin continues to spread over his entire body.

The skin condition can start at any age but is more common in adults under 35.

The patches of skin normally appear on the elbows, knees, scalp and lower back, but can appear anywhere on the body.

Most people are only affected with small patches.

In some cases, the patches can be itchy or sore.

AsiaWire

There is no known cure for psoriasis,but a range of treatments can improve symptoms and the appearance of skin patches.

In most cases, the first treatment used will be a topical treatment, such as vitamin D analogues or topical corticosteroids.

Topical treatments are creams and ointments applied to the skin.

AsiaWire

Li, fromWeihui city, in Central Chinas Henan Province, claims his condition was triggered by a hairdresser who accidentally cut his scalp in the 1950s.

Li has spent more than 11,350 trying to find a cure for his condition but doctors have been unable to relieve his symptoms.

Theyhave also been unable to find a link between his condition and his hairdresser theory.

Li, who never married, was built a special home inside his village so he could live in isolation.

The villagers have dubbed him bark man and, while they claim they are used to seeing Li walk around their neighbourhood, they fear his condition could spread to others.

Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

These patches normally appear on your elbows, knees, scalp and lower back, but can appear anywhere on your body.

Most people are only affected with small patches. In some cases, the patches can be itchy or sore.

It affects around two per cent of the UK population.

Why does it happen?

People with psoriasis have anincreased production of skin cells.

Skin cells are normallymade and replaced every three to four weeks, but in psoriasis this process only lasts about three to seven days.

The resulting build-up of skin cells is what creates the patches associated with psoriasis.

It is thought to be a problem with the immune system and can run in families.

How is it treated?

Theres no cure for psoriasis, but a range of treatments can improve symptoms and the appearance of skin patches.

In most cases, the first treatment used will be a topical treatment, such as vitamin D analogues or topical corticosteroids.

Topical treatments are creams and ointments applied to the skin.

If these arent effective, or your condition is more severe, a treatment called phototherapy may be used.

Phototherapy involves exposing your skin to certain types of ultraviolet light.

In severe cases, where the above treatments are ineffective, systemic treatments may be used. These are oral or injected medicines that work throughout the whole body.

Source: NHS

We pay for your stories! Do you have a story for The Sun Online news team? Email us attips@the-sun.co.ukor call 0207 782 4368

Visit link:
Man with skin as rough as TREE BARK lives with agonising disease that makes his body 'crack' - The Sun

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Psoriasis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report to their offering.

The Global Psoriasis Treatment Market was valued at US$ 7.9 Bn in 2016, and is expected to reach US$ 12.8 Bn by 2025, expanding at a CAGR of 5.4% from 2017 to 2025.

The psoriasis treatment market is rapidly growing due to factors such as growing prevalence in some countries, significant unmet needs, promising pipeline molecules would drive the growth of psoriasis market worldwide. For the purpose of study, global psoriasis treatment market is segmented on the basis of drug class such as TNF Inhibitors, Vitamin D analogues, interleukin blockers and other psoriasis medication. It is observed that, in the base year 2016, interleukin blockers was major revenue contributing segment due to its long-term safety with lower risk of infection and malignancy. Psoriasis treatment market is categorized on the basis of route of administration such as topical, oral and parenteral therapeutic drugs.

Currently, topical therapeutic drugs hold largest market share due to its safety, more effectiveness and targeted drug delivery. It is anticipated that parenteral therapeutic drugs would show significant growth during forecast period because newly approved biologics are generally preferred in moderate to severe psoriasis.

Companies Mentioned

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Psoriasis Treatment Market Analysis

Chapter 4 Global Psoriasis Treatment Market, by Drug Class

Chapter 5 Global Psoriasis Treatment Market, by Route of Administration

Chapter 6 Global Psoriasis Treatment Market, by Geography

Chapter 7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/wnpcpw/global_psoriasis

Here is the original post:
Global Psoriasis Treatment Market to Reach $12.8 Billion by 2025 ... - Business Wire (press release)

The European Commission (EC) approved Almiralls oral dimethyl fumarate (DMF) drug Skilarence as first-line induction and maintenance therapy for adults with moderate-to-severe plaque psoriasis. The firm said it plans to start marketing the drug in all EU member states, Iceland, and Norway during the third quarter of 2017

Spanish firm Almirall said Skilarence is the first fumaric acid ester (FAE) approved by the EC for treating psoriasis. Regulatory clearance was based on data from the placebo-controlled Phase III BRIDGE study comparing the efficacy and safety of the oral drug Skilarence with the oral FAE drug Fumaderm, which is approved in Germany but not across Europe.

Fumaric acid esters are a recommended oral systemic therapy for psoriasis and recommended in the European guidelines for induction and long-term maintenance therapy. Commenting on approval of Skilarence in Europe, Eduardo Sanchiz, Almirall's CEO, said "The EC's approval is very good news for healthcare professionals and for a large number of European patients, who will have access to a new therapeutic option for the systemic treatment of moderate-to-severe psoriasis. Skilarence is the result of Almirall's commitment to innovation, and making it available to doctors and their patients with psoriasis will constitute a very important step in reinforcing the company's position as significant player in the field of dermatology".

Almiralls dermatology portfolio accounted for 51% of its total 764.4 million (approximately $863 million) net sales in 2016. Dermatology sales during 2016 were up 32.1%, at 390 million (approximately $440 million).

Last month the firm established a collaboration with Leo Pharma to develop a painless, minimally invasive skin sampling method to aid biomarker analysis in research and clinical trials.

Originally posted here:
Almirall Wins EC Nod for Oral DMF Psoriasis Drug Skilarence - Genetic Engineering & Biotechnology News (press release)

Prevention.com

Here's Why We Need To Start Talking About Psoriasis, Says ... Prevention.com Olympic swimmer Dara Torres shares what it's like to live with psoriasis and talks about the Show More Of You campaign. Swimmer Dara Torres is still defying age with exercise - TODAY.comToday.com all 3 news articles »

Go here to read the rest:
Here's Why We Need To Start Talking About Psoriasis, Says ... - Prevention.com

About psoriatic arthritis. (n.d.). Retrieved from https://www.psoriasis.org/about-psoriatic-arthritis

Barrea, L., Savanelli, M. C., Di Somma, C., Napolitano, M., Megna, M., Colao, A., & Savastano, S. (2017, February 7). Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Review in Endocrine and Metabolic Disorders 17(66), 1-11. Retrieved from https://link.springer.com/article/10.1007%2Fs11154-017-9411-6

Biologic medications for psoriasis. (2014, August). Retrieved from http://www.consumerreports.org/cro/2014/08/biologics-for-psoriasis/index.htm

Boehncke, W.-H., & Schon, M. (2015, September 5). Psoriasis [Abstract]. The Lancet, 386(9997), 983-994. Retrieved from http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61909-7/abstract

Cline, A., Hill, D., Lewallen, R., & Feldman, S. (2016, July 6). Current status and future prospects for biologic treatments of psoriasis [Abstract]. Expert Review of Clinical Immunology, 12(12), 1273-1287, Retrieved from http://www.tandfonline.com/doi/full/10.1080/1744666X.2016.1202115

Di Meglio, P., Villanova, F., & Nestle, F. O. (2014, August). Psoriasis. Cold Spring Harbor Perspectives in Medicine, 4(8), a015354. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109580/ Gibson, L. E. (2016, December 1). Can changing my diet treat psoriasis? Retrieved from http://www.mayoclinic.org/diseases-conditions/psoriasis/expert-answers/psoriasis-diet/FAQ-20057925

Jensen, P., & Skov, L. (2017, February 23). Psoriasis and obesity. Dermatology. Retrieved from https://www.karger.com/Article/FullText/455840

Lewinson, R. T., Vallerand, I. A., Lowerison, M. W., Parsons, L. M., Frolkis, A. D., Kaplan, G. G., Barnabe, C. (2017, April). Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: A population-based study [Abstract]. The Journal of Investigative Dermatology 137(4), 828-835. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28237512

Mahil, S. K., Capon, F., & Barker, J. N. (2016, January). Update on psoriasis immunopathogenesis and targeted immunotherapy. Seminars in Immunopathology, 38(1), 11-27. Retrieved from http://doi.org/10.1007/s00281-015-0539-8

Mason, A. R., Mason, J., Cork, M., Dooley, G., & Hancock, H. (2013, March 28). Topical treatments for chronic plaque psoriasis. The Cochrane Database of Systemic Reviews, 3. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23543539

Mayo Clinic Staff. (2015, June 17). Psoriasis: Alternative medicine. Retrieved from http://www.mayoclinic.org/diseases-conditions/psoriasis/basics/alternative-medicine/con-20030838

Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Bhushan, R. (2008, May). Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 58(5), 826-850. Retrieved from http://www.jaad.org/article/S0190-9622(08)00273-9/fulltext#sec4

Ogdie, A., Yu, Y., Haynes, K., Love, T. J., Maliha, S., Jiang, Y., Gelfand, J. M. (2015). Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Annals of the Rheumatic Diseases, 74(2), 326-332. Retrieved from http://doi.org/10.1136/annrheumdis-2014-205675

Psoriasis. (2016, February 9). Retrieved from https://www.cdc.gov/psoriasis/

Psoriasis. (n.d.). Retrieved from https://www.aad.org/media/stats/conditions/psoriasis Whats tops in, topical steroid treatments? (n.d.). Retrieved from https://www.psoriasis.org/about-psoriasis/treatments/topicals/steroids/potency-chart

Read more from the original source:
How Are Psoriasis and Psoriatic Arthritis Connected? | EmpowHER ... - EmpowHer

Living with psoriasis can be a roller coaster ride: Sometimes you may be fighting flares while other times the condition may not have any noticeable symptoms. Knowing how to manage this autoimmune condition can make your life much easier and more comfortable.

Youve got many options for staying ahead of psoriasis even though it has no cure. Effective management of the condition includes:

There are many types of psoriasis. Each type requires different management plans based on the severity of the condition and where its located on your body. You must also factor in your other health conditions that may be related to psoriasis. Your doctor can devise a plan that works best for you.

Dont ignore symptoms of psoriasis. Because theres no cure, it needs to be managed by a doctor. What appears as a mild case may worsen with time, and your doctor can decide how to keep the condition from spreading.

Mild psoriasis can generally be treated with topical methods. Psoriasis that is moderate or severe in nature may require stronger interventions. These include:

Psoriasis is associated with other health conditions, such as:

Your doctor should check for these other conditions when treating psoriasis.

A recent trend in psoriasis management includes the treat to target approach. This concept allows you to evaluate your treatments with a doctor on a periodic basis. Together, you determine if the devised plan is effective in reducing your symptoms. Such a treatment plan should have overall goals for reducing your symptoms and allow for modifications from both you and your doctor every few months.

Several studies affirm this method of evaluation in managing psoriasis. Archives of Dermatological Research concluded that those who have outcomes measurement for their psoriasis experience:

Talk to your doctor about coming up with a regular schedule for evaluating your treatment plan. Goals should be individual in nature and may include:

It may be tempting to discontinue your psoriasis treatments if your condition seems under control. You may not be experiencing any psoriasis flare-ups and forget to take prescribed medications or keep up with a daily skin care routine. This can result in the condition coming back or even getting worse.

Consult your doctor if you feel that your treatment plan could be modified based on any reduced symptoms. Youll want to ensure that modifying treatments will result in fewer symptoms in the long term.

Maintaining a healthy weight can help prevent your psoriasis from spreading or flaring. Some studies link worsening psoriasis symptoms with a higher-than-average body mass index. One analysis in the Journal of Cutaneous Medicine and Surgery found that increased body mass index resulted in the development of more severe psoriasis.

Losing weight may help psoriasis symptoms in those who are obese or overweight. One study in the British Journal of Dermatology analyzed overweight and obese participants who had psoriasis. The participants exercised and dieted for 20 weeks, resulting in a reduction in the severity of their psoriasis.

Talk to your doctor about weight loss methods if you are obese or overweight. This may include reducing the calories in your diet and exercising more frequently. Losing weight will help your overall health and may reduce other health conditions you have. Exercising itself is considered to be a great way to manage psoriasis symptoms.

Smoking and drinking alcohol can aggravate psoriasis. Smoking can cause psoriasis to develop or become more severe. Drinking alcohol may worsen the condition or interfere with treatments. Eliminate these unhealthy lifestyle habits to reduce psoriasis symptoms.

Stress can negatively affect psoriasis by causing your immune system to overreact. Activities like yoga, meditation, and mindfulness may reduce stress. You should also examine what factors in your life cause stress and work to eliminate these triggers.

You may also find yourself struggling with mental health because of psoriasis. Anxiety and depression are commonly tied to psoriasis and should be treated immediately. Mental health conditions can affect the management of psoriasis as well as increase your risk for suicide.

There are many ways you can manage your psoriasis to prevent flares and reduce the conditions severity. Seeing your doctor should be the first step in getting on top of psoriasis.

Its important to keep in mind that psoriasis isnt curable, and at times symptoms can pop up despite your best efforts to control the condition. You should check in with your doctor regularly to evaluate the condition and to prevent it from getting worse.

Fleming, P., Kraft, J., Gulliver, W. P., & Lynde, C. (2015, May 7). The relationship of obesity with the severity of psoriasis: A systematic review. Journal of Cutaneous Medicine and Surgery, 19(5). Retrieved from http://journals.sagepub.com/doi/abs/10.1177/1203475415586332

Mrowietz, U., Steinz, K., & Gerdes, S. (2014, August 2). Psoriasis: To treat or manage? Experimental Dermatology, 23(10), 705-709. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/exd.12437/full

Naldi, L., Conti, A., Cazzaniga, S., Patrizi, A., Pazzaglia, M., Lanzoni, A., The Psoriasis Emilia Romagna Study Group. (2014, March 12). Diet and physical exercise in psoriasis: A randomized controlled trial. British Journal of Dermatology, 170(3), 634-642. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/bjd.12735/full

National Psoriasis Foundation. (n.d.). Psoriasis and mental health issue brief. Retrieved from https://www.psoriasis.org/sites/default/files/life-with-psoriasis/PsoriasisandMentalHealthIssueBriefonepager20140225.pdf

National Psoriasis Foundation. (2015, May 6). How cigarettes and alcohol affect psoriasis. Retrieved from https://www.psoriasis.org/advance/how-cigarettes-and-alcohol-affect-psoriasis

National Psoriasis Foundation. (2017, January 1). Your disease is under control now what? Retrieved from https://www.psoriasis.org/advance/disease-under-control-now-what

Psoriasis and smoking. (n.d.). Retrieved from http://www.papaa.org/further-information/psoriasis-and-smoking

Psoriasis treatments. (n.d.). Retrieved from https://www.psoriasis.org/about-psoriasis/treatments

Radtke, M. A., Reich, K., Sephr, C., & Augustin, M. (2015, July). Treatment goals in psoriasis routine care. Archives of Dermatological Research, 307(5), 445-449. Retrieved from http://link.springer.com/article/10.1007/s00403-014-1534-y

Stress and psoriatic disease. (n.d.). Retrieved from https://www.psoriasis.org/life-with-psoriasis/stress

Treat 2 target. (n.d.). Retrieved from https://www.psoriasis.org/treat-to-target

Read more from the original source:
6 Ways to Stay Ahead of Your Psoriasis - EmpowHer

As an inhibitor of an inflammatory protein associated with the development of psoriasis, adalimumab shows promise as a therapy for pediatric patients with severe plaque psoriasis. Adalimumab treatment for 16 weeks in children and adolescents with severe plaque psoriasis provides significant improvements compared to methotrexate.

Psoriasis is a chronic skin condition characterized by scales and red patches that are typically found on the scalp, elbows, and knees. This buildup of extra skin cells on the surface of the epidermis is an autoimmune inflammatory disease, which is currently incurable. Immune system T-cells and an abundance of inflammatory protein tumor necrosis factor-alpha (TNF-) play major roles in the development of psoriasis. Though there are many types of psoriasis, plaque psoriasis is the most common condition which involves the build-up of plaque on the surface of the skin. Itching, burning, soreness, or cracked skin are some of the symptoms associated with the disease and its severity can be classified as mild, affecting less than 5% of the skins surface area, moderate, affecting 5 to 10% of the skin, or severe, with more than 10% of the skins surface affected. Affecting 2% of the general population, a third of psoriasis diagnoses made by physicians include those who are 20 years of age and younger.

Management of pediatric psoriasis can decrease the risk of psychosocial issues and comorbidities such as, hypertension and diabetes. Initial treatment for patients with limited disease includes topical therapies, while severe pediatric psoriasis is treated using ultraviolet B phototherapy, or systemic treatments, such as methotrexate, ciclosporin, or retinoids. However, though TNF- inhibitor, methotrexate, has been prescribed to treat children and adolescents, it has not been approved by the European Medicine Agency, thus making it a good candidate for clinical research assessment. Due to the lack of standardized guidelines and approved systemic therapies, managing psoriasis by the blockage of TNF-, has been challenging. However, in 2015, TNF- inhibitor, adalimumab, was approved in the United States to treat severe cases in patients who were 4 years of age and older, and who did not respond adequately to topical therapy or phototherapies. Therefore, it is important to compare both inhibitors for their safety and efficacy in treating severe pediatric plaque psoriasis.

A double-blind randomized controlled study was performed to compare the safety and efficacy of adalimumab and methotrexate in children with severe psoriasis. Treatment groups consisted of a total of 114 patients who were randomly assigned to receive either 0.8 mg/kg of adalimumab, 0.4 mg/kg of adalimumab, or 0.1-0.4 mg/kg of methotrexate. Adalimumab was given subcutaneously every other week, whereas, methotrexate was taken orally once weekly. The study consisted of four periods; identified as the 16-week primary treatment, up to 36-week withdrawal, 16-week re-treatment, and 52-week long-term follow-up. Measurements based on the Psoriasis Area and Severity Index (PASI) assessed the percentage of skin affected and 75% improvement, PASI75, was a study endpoint. The Physician Global Assessment (PGA), which measures psoriasis activity, was used to identify clear or minimal areas. At week 16, PASI75 was achieved in 58% of the patients receiving 0.8mg/kg of adalimumab, in 44% of patients receiving 0.4 mg/kg of adalimumab, and in 32% of patients taking methotrexate. Results from the PGA showed 61% of patients receiving 0.8mg/kg of adalimumab, 41% of patients receiving 0.4 mg/kg adalimumab, and 41% of patients taking methotrexate had a clear or minimal PGA score. Initial treatments resulted in adverse events, such as infections for 45% of the patients receiving 0.8 mg/kg of adalimumab, in 56% of the patients receiving 0.4 mg/kg of adalimumab, and in 51% of those taking methotrexate. Compared to methotrexate, treatment with adalimumab in children and adolescents with severe plaque psoriasis provided significant improvements in PASI75. Although there was an increase in the number of patients with a clear or minimal PGA score in the adalimumab group compared to methotrexate, these results did not reach statistical significance. Overall, adalimumab was found to be more effective than methotrexate, with a rapid response and similar safety profile after 16 weeks.

This study is one of few investigations that characterize the long-term safety of treatment of severe psoriasis in children. Though a limitation of the study was a lack of methotrexate control data to compare to the investigated population, the safety and efficacy profile of adalimumab was successfully evaluated for comparison to methotrexate. In conclusion, treatment with 0.8 mg/kg of adalimumab for 16 weeks in children and adolescents with severe plaque psoriasis provided significant improvements in PASI75 and a non-significant increase in patients who achieved clear or minimal PGA compared with methotrexate. These findings provide new insight and an additional option for safe and effective therapy of severe plaque psoriasis in a young population.

Written By:Viola Lanier, Ph. D., M. Sc.

Add to Flipboard Magazine.

See more here:
Adalimumab Safe and Effective Therapy for Pediatric Psoriasis - Medical News Bulletin

Local research study could help psoriasis patients

Shannon Valladolid, WTSP 11:32 PM. EDT June 25, 2017

Imagine living with a skin condition that leaves severe rashes all over your body.

We're talking about Psoriasis.

For years, people suffering from the condition had only one option to get rid of it, painful weekly injections.

For the past 8 years, Olga Clark has given herself two injections every week to treat her Psoriasis.

I couldn't take a bath because the water burned my skin. My scalp was really severe to where I would scratch and I felt like I was bleeding, says Clark.

She no longer has rashes on her skin, now but Olgas says at its peak, psoriasis took over her body.

There was not a spot on me that was clear. my legs were covered, everything was covered, says Clark.

In 2014, the first pill finally hit the market called Otezla.

In an effort to challenge the only that pill, Dr.Seth Forman, who is the Principal Investigator with Forward Clinical Trials, is conducting a local research study to put a new pill in the hands of patients like Olga.

Olga is one of hundreds of patients that I have on these injectable medications. I can tell you most, if not all would rather take a pill like they do for their cholesterol or their blood pressure, says Dr.Forman, MD.

Dr. Forman says the downside to only having one pill option is some patients could have an allergic reaction, then it's back to injections. That's why he says clinical research is so important.

In order for us to get there for other skin conditions like Psoriasis, eczema. The only way we can do that is by having these what I call heroes participate in clinical research, he says.

Giving people living with severe skin conditions, an option to possibly not feel the pain of a needle.

If it didn't have to take a shot I would be happy. For them just to get on a pill, I think that's going to be great for them, says Clark.

Otezla has mixed reviews. Some complain they have severe side effects. But others say its really helped them deal with their condition.

Forward Clinical Trials is also working on research studies for treating the following:

To learn more regarding these studies or how you can get involved click here.

2017 WTSP-TV

Originally posted here:
Local Clinical research could give more options for patients suffering from psoriasis - WTSP 10 News

KNOXVILLE (WATE) Quinn Perkins, played by Actress Katie Lowes is one tough cookie on the show Scandal, but she is also tough in real life.

Lowes has lived with a chronic autoimmune disease known as psoriasis for the past eight years. She says she was diagnosed with psoriasis eight years ago but finally decided to go public with her experiences in the hopes of helping others.

When I was first diagnosed I was so embarrassed and ashamed. You know, being an actress in Hollywood, there is such a pressure to look a certain way and after living with it for eight years, says Lowes, Im really living my best life and I thought there are 7.5 million other Americans living with this disease and if I can help even one of them feel inspired to be there own best advocate to get to a place where they are living their fullest life and theyre not limiting themselves because of psoriasis, then that would just be a huge win.

The actress is partnering with Jansen and the National Psoriasis Foundation on a campaign called Inside Story. She shares her story about living with psoriasis and encourages others to do the same.

While on the set of Scandal, Lowes said there were times when she had flare-ups. She said there were times when she couldnt wear a certain red carpet look or wear a bathing suit on vacation.

There are all these limitations placed on your life and I know from personal experience it can be so upsetting and you can feel so alone, but with 7.5 million people living with this disease, you are not, said Lowes. This site is a wonderful tool that people struggling with psoriasis can use to their benefit because I want people to feel, you know, that we are a large community that we support each other. I want to encourage people to find a doctor they can trust, to find a treatment that works for them and I just want people to know that it is possible to get to a place where youre not limiting fashion and style and being with our family and things like that.

Lowes appears on the final season of Scandal which airs Thursdays on WATE 6 On Your Side. When asked if she knows how the show will end, Lowes said she is under lock-and-key.

We are not allowed to say anything, but I can assure you that this will be the final season of Scandal and the writers are leaving it all on the dance floor and it is going to be a wild and crazy ride for sure.

Read more from the original source:
'Scandal' actress Katie Lowes opens up about psoriasis - WATE 6 On Your Side

Liam Gallagher (Picture: Rex)

Bad boy rocker Liam Gallagher has many a vivid tale of debauchery to proudly share with the world but this particular story makes even him scratch his head in disbelief.

The former Oasis frontman recalled upon his first experiences of Glastonbury, when the band first played the festival in 1994 and told a backstage story in which a fan mistook hispsoriasis a flaky and itchy skin condition for cocaine.

I remember coming off stage and I got my clothes robbed, told Liam in a recent interview with Noisey.

I remember meeting someone, some very strange kid, who come up to me and thought I had cocaine in my hair, he said.

I got psoriasis so I had obviously been scratching it during the day and that, and there were little white bits and shit, the singer eloquently put.

They were takingit out of my hair and putting it on their gums and putting it up their fucking nose. I went like, Okay

I think we were a bit too laddy or English for them the Morning Glory singer added.

Miley Cyrus praises role model Dolly Parton as she reveals why she feels 'genderless'

10 pictures of Glastonbury day 2 looking amazing

Glastonbury to hold minute's silence to honour victims of London and Manchester attacks

Meanwhile, Liam was also confirmed to appear at Worthy Farm on the Pyramid Stage this year, as well as showing that he also has the chops for spitting grime bars.

Speaking to Christian OConnell on Absolute Radio, he told how his second son Gene really likes the Skepta stuff prompting the host to encouraging the Wonderwall hitmaker to have a go at so-called Skepta stuff.

It was a little inaudible at first but on a second listen we could tell that he rapped: You aint road! The only road you sweep are paved with gold.

Liam has reportedly finished work on his solo album As You Were, and will release it in the autumn only a month before brother Noels new album.

We wonder how much of his sons grime influence will have on his new record.

MORE: Liam Gallaghers had a pop at Liam Payne, just for a change

MORE: Skepta ave it mate: You need watch Liam Gallagher spit some grime

See the original post:
Oasis fan mistook Liam Gallagher's psoriasis for cocaine at ... - Metro - Metro